Ronald A R, Silverblatt F, Clark H, Cutler R E, Turck M
Appl Microbiol. 1971 Jun;21(6):990-2. doi: 10.1128/am.21.6.990-992.1971.
The differentiation of renal from bladder bacteriuria is difficult on clinical grounds alone. To evaluate the correlation between site of infection and urinary beta-glucuronidase activity, 46 patients with well documented recurrent bacteriuria were studied by bilateral ureteral catheterization. Urinary beta-glucuronidase activity was also determined in 46 control subjects. In general, asymptomatic patients with renal bacteriuria, either unilateral or bilateral, had levels of enzyme activity in their urine comparable to patients with infection confined to the bladder and to normals. Only 4 of 25 patients with renal bacteriuria had significant elevations of urinary beta-glucuronidase. After localization of infection, 9 of 10 patients treated with kanamycin, a potentially nephrotoxic drug, developed significant elevations of urinary beta-glucuronidase. The results of these studies indicate that determination of beta-glucuronidase activity in urine is not useful in predicting the site of infection in patients with bacteriuria but may find a role in screening for early nephrotoxicity.
仅根据临床症状很难区分肾盂菌尿和膀胱菌尿。为评估感染部位与尿β-葡萄糖醛酸酶活性之间的相关性,对46例有明确复发性菌尿记录的患者进行了双侧输尿管插管研究。还测定了46例对照者的尿β-葡萄糖醛酸酶活性。一般来说,无论是单侧还是双侧肾盂菌尿的无症状患者,其尿液中的酶活性水平与局限于膀胱感染的患者及正常人相当。25例肾盂菌尿患者中只有4例尿β-葡萄糖醛酸酶有显著升高。在确定感染部位后,10例接受可能具有肾毒性的药物卡那霉素治疗的患者中有9例尿β-葡萄糖醛酸酶显著升高。这些研究结果表明,测定尿中β-葡萄糖醛酸酶活性对预测菌尿患者的感染部位并无帮助,但可能在早期肾毒性筛查中发挥作用。